How many insider trades does FilingIQ track for ALMS?

FilingIQ tracks 152 Form 4 insider transactions for ALMS (ALUMIS INC.), covering filings from Jul 1, 2024 onwards. 12 of those were filed in the last 90 days.

Are ALMS insiders net buyers or net sellers?

Across the full Form 4 history for ALMS, 55 transactions (36%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ALMS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ALMS in?

ALUMIS INC. (ALMS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.16B.

ALMS insider trading

NasdaqGS Healthcare

ALUMIS INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

152

Last 90 days

Buys / sells

36% / 0%

Market cap

$3.16B

About ALUMIS INC.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Company website: www.alumis.com

ALMS insider activity at a glance

FilingIQ has scored 152 insider transactions for ALMS since Jul 1, 2024. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 55 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ALMS insider trades is 52.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ALMS trades on FilingIQ Raw filings on SEC EDGAR

Latest ALMS Form 4 filings

AKKARAJU SRINIVAS

P Dec 2, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding ALMS

Opaleye Management Inc.

$5.22M · 0.7% of AUM

Frequently asked

How many insider trades does FilingIQ track for ALMS?: FilingIQ tracks 152 Form 4 insider transactions for ALMS (ALUMIS INC.), covering filings from Jul 1, 2024 onwards. 12 of those were filed in the last 90 days.
Are ALMS insiders net buyers or net sellers?: Across the full Form 4 history for ALMS, 55 transactions (36%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ALMS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ALMS in?: ALUMIS INC. (ALMS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.16B.

Methodology & sources

Every ALMS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.